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ABSTRACT 
Historically, quantitative health risk assessment of chemical substances is based on 
deterministic approaches. For a more realistic and informative health risk assessment, however, 
the variability and uncertainty inherent in measurements should be taken into consideration. 
The variability and uncertainty may be assessed by applying probabilistic methods when 
performing dose-response assessment, exposure assessment and risk characterization.  
The benchmark dose (BMD) method has been suggested as an alternative to the no observed 
(adverse) effect level (NO(A)EL) approach in dose-response assessment of non-cancer health 
effects. In contrast to the NO(A)EL that is limited to being one of the experimental dose levels, 
the BMD is estimated as the dose corresponding to a predetermined change in response, 
according to a model fitted to the dose-response data. 
In the present thesis, quantitative differences in sensitivity between dioxin sensitive Long-
Evans (L-E) and dioxin resistant Han/Wistar (H/W) rats following long-term exposure to 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)  was investigated. Sensitivity differences were 
analyzed by comparing BMDs for the two strains, considering a number of conventional 
toxicological endpoints, endpoints relevant for the endocrine system, and a group of bone 
parameters. Differences between the strains were most pronounced for hepatic foci; L-E rats 
were approximately 20-40 times more sensitive than H/W rats. For body and organ weight 
parameters, L-E rats were 10-20 times more sensitive than H/W rats. For retinoid parameters 
and hepatic CYP1A1 induction, estimated differences between the strains were generally 
about 5-fold. For bone effects, significant strain differences were observed with the L-E rat 
being the most sensitive strain. This difference was most pronounced (about 49-fold) for 
cross-sectional area of proximal tibia. It was also concluded that the BMD approach is a more 
suitable method for evaluation of bone parameters compare to the NOAEL approach. In 
another application, relative potency values (REPs) were established for a group of dioxin-
like (DL) and non-dioxin-like (NDL) polychlorinated biphenyl (PCB) congeners as the ratio 
between BMDs, median effective doses (ED50s), or NOELs. This analysis was based on 
increased liver weight, decreased hepatic vitamin A levels, and increased hepatic EROD 
activity. The findings indicated that the BMD approach results in more reliable REP values 
compared to the ED50 and NOEL approaches. The BMD approach also provides more 
information about the precision of the estimated REP values by the calculation of a two-sided 
90% confidence interval; a confidence interval may also be established for a ED50 ratio but 
not for a NO(A)EL ratio. Overall findings in this analysis supported further development and 
use of endpoint specific systems for assessment of human exposure to mixtures of chemicals 
with similar as well as different mode-of-actions. 
Finally, the potential health impact of a group of PCBs was characterized by estimating the 
cumulative margins of exposure (MOEs) for the adult Swedish population. A cumulative 
MOE distribution was quantified by simultaneous integration of a reference dose (RfD) 
distribution and a distribution for the human dietary exposure. Both a relative potency factor 
(RPF) based approach and an RPF-free approach were used for estimating the cumulative 
MOE. Results indicated that the cumulative MOE could be up to four times lower for women 
compared to men. The cumulative MOE reflected the MOE for PCB 126; other PCB congeners 
had little contribution. Compared to conventional MOE approaches, the newer approaches 
considered herein provide an improved tool under which potential health concerns can be 
assessed by accounting for both variability and various uncertainties, quantitatively, 
contributing to improving cumulative health risk assessments for the human population.  
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1 BACKGROUND 
 
Humans are continuously exposed to a variety of compounds present in the 
environment and in food.  Human health risk assessments are performed to assess the 
risk of adverse health effects of exposure to chemical substances. According to the 
World Health Organization (WHO) this process consists of four different steps; hazard 
identification, hazard characterization, exposure assessment and risk characterization 
(WHO/IPCS 2004). 
 
The first step is to identify the type and nature of the adverse health effects that an 
agent has the capability to cause in an organism, system or population. The aim of 
hazard identification is to identify the potential critical endpoints that can be assumed to 
be relevant for humans. The second step, hazard characterization (dose-response 
assessment) involves investigating the relationship between the administered or 
absorbed dose of a chemical and the adverse effects it may produce in more detail. This 
assessment mostly relies on data from experimental animal studies, while consideration 
of data from human epidemiological studies is made from time to time. The overall aim 
of the hazard characterization is to determine the dose below which the compound of 
interest does not cause adverse health effects in humans. This is the estimated 
maximum exposure level of an agent, normally expressed on a body mass basis, to 
which individuals in a (sub) population may be exposed over a lifetime without 
appreciable health risk. Various terms are used to for such health-based guidance 
values; for example acceptable daily intake (ADI), tolerable daily intake (TDI) (the 
term “tolerable” is used for agents that are not deliberately added, such as contaminants 
in food), reference dose (RfD), and reference concentration (RfC). ADI/TDI are terms 
used e.g. by the WHO and the European Food Safety Authority (EFSA), while 
RfD/RfC are used by the U.S. Environmental Protection Agency (EPA). In this thesis 
the term RfD will be used. The RfD is estimated by applying uncertainty factors, such 
as inter- and intra-species factors, to a point of departure (PoD) derived from the dose-
response assessment.  
 
Exposure assessment involves estimating the exposure, via one or multiple routs, to a 
particular agent in a population of interest. The average exposure alone is a poor 
descriptor of the exposure in a population. Thus, assessment of the potential variation in 
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exposures is an important part of this step. More recently, there is also a focus towards 
assessing the uncertainty, besides the variability.  
 
Risk characterization involves the integration of the first three steps in the risk 
assessment process.  Ideally, it should produce a quantitative estimate of the risk in the 
exposed population, and/or estimates of the potential risk under different plausible 
exposure scenarios. Such estimates may be derived by combing the exposure 
information with information on the relationship between dose/exposure and the 
adverse health effect of interest. The potential health concern for a particular agent is 
often assessed by estimating the margin of exposure (MOE) or margin of safety 
(MOS), which involves comparison of the exposure situation with PoDs or reference 
points (RPs, i.e. equivalent to PoDs) derived in the dose-response assessment (Renwick 
et al. 2003; WHO 1999). 
 
The current thesis mainly relates to hazard characterization, but it also deals with 
exposure assessment and risk characterization to some extent. Even though human data 
sometimes is used for hazard characterization the case of using animal data as a basis is 
exclusively considered. The main objective within this work is the further development 
and application of new methods for quantitative health risk assessment of chemicals. 
 
1.1 HAZARD CHARACTERIZATION 
1.1.1 Threshold vs. non-threshold assumption 
Traditionally, different assumptions have been made regarding the shape of the dose-
response relationship in the low dose region depending on whether a non-genotoxic or 
a genotoxic effect is considered. For non-genotoxic effects an exposure threshold is 
assumed; i.e. there exists a dose level below which no biologically significant effects 
are observed. Since only differences in response that are higher than the experiment 
detection limit can be identified, it is hard to prove or disprove the presence of a 
threshold from the experimental data (Slob 1999). Therefore the existence of a 
threshold should be supported by expert judgment of the underlying biology of the 
effect. For genotoxic carcinogens, however, it has theoretically been regarded that even 
a single molecule of genotoxicants could damage DNA, leading to the development of 
a tumor. Therefore, a non-threshold assumption is considered for genotoxic 
carcinogens.  
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The present thesis relates to risk assessment based on non-gentoxic effects, such as 
organ weight effects, alteration of tissue retinoid levels, changes in bone parameters 
and it does not specifically discuss the case of genotoxic carcinogens. 
 
1.1.2 The NO(A)EL approach 
A purpose of the dose-response assessment is to specify the highest dose without 
appreciable risk (effect). Traditionally, the no-observed-adverse-effect-level (NOAEL) 
is used as the PoD for the establishment of such health-based guidance values (e.g. 
RfDs) when the health risk assessment is based on non-genotoxic effects. The NOAEL 
is usually derived from animal data, and is defined as the highest experimental dose 
level for which the (mean) response is not significantly different compared with the 
(mean) response in the control group (threshold assumed). The effects that are 
considered for derivation of a NOAEL should also be toxicologically relevant effects, 
meaning that they should be relevant to human health risk. Since, it is very difficult if 
not impossible to judge the health relevance of an induced effect, some has supported 
the use of the term no-observed-effect-level (NOEL) (Berry 1988). If a NO(A)EL 
cannot be derived, the lowest-observed-(adverse)-effect-level (LO(A)EL) is used 
instead and is extrapolated to NO(A)EL by the application of an extrapolation factor. 
The final PoD is normally determined as the lowest relevant NO(A)EL, among the 
potentially critical effects, in the critical study/s.  For establishment of health based-
guidance values for human, uncertainty factors are applied to the PoD. 
 
In this thesis the term NOAEL/LOAEL will be used when a studied endpoint can be 
considered as an adverse toxicological effect and the term NOEL/LOEL will be used 
when the investigated endpoint is not considered to be toxic per se but rather a marker 
of toxicity.  
 
1.1.3 The Benchmark dose approach 
Several limitations have been associated with the NO(A)EL approach (Crump 1984; 
Davis et al. 2011; USEPA 1995). Due to these shortcomings, the benchmark dose 
(BMD) approach was introduced by Crump (1984) as an alternative method. The BMD 
approach involves fitting of a mathematical model to the dose-response data and 
estimating the BMD as the dose corresponding to a predetermined change in the 
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response, referred to as the benchmark response (BMR). The BMD approach is 
illustrated in Figure 1. This concept was initially discussed for quantal dose-response 
data with a focus towards developmental toxicity (Allen et al. 1994a, 1994b; Faustman 
et al. 1994; Kavlock et al. 1995). However, this approach is now also frequently applied 
to (experimental and epidemiological) continuous data (Budtz-Jorgensen et al. 2001; 
EFSA 2009b; Sand et al. 2004; Slob 2002). 
 
For determination of health-based guidance values using the BMD approach the 
extrapolation/uncertainty factors are applied to the lower confidence bound of BMD, 
i.e. the BMDL, instead of the NO(A)EL. The BMDL is usually defined as the one-
sided lower 95% confidence limit on the BMD (which equals the lower bound of a 
two-sided 90% confidence interval); it can be interpreted as the dose corresponding to a 
response not likely to be larger than the specified BMR (with 95% confidence). Studies 
with larger sample sizes will produce tighter confidence intervals and therefore result in 
larger BMDLs (considering all else equal). 
 
The fact that the BMD approach accounts for sample size, by assessing the statistical 
uncertainty associated with the BMD, has been regarded as a major advantage relative 
to the NO(A)EL approach. When increasing the sample size of the experiment the 
power of the test to detect an effect increases; if there are significant differences 
between groups it is easier to detect this as the sample size increases (i.e. the NO(A)EL 
decreases). The opposite characteristics have been discussed to be more appropriate 
from regulatory viewpoint arguing that larger experiments should provide a greater 
evidence of safety and therefore result in a higher PoD, which is theoretically the case 
for the BMD approach. Because the BMD concept uses the entire data instead of 
comparing each dose group against the control, it should also be less sensitive to study 
design and experimental error compared to the NO(A)EL approach. The shape of the 
dose-response relationship is also taken into account to a higher extent relative to the 
case when using a NO(A)EL. 
 
Another advantage of using the BMDL is that the PoD for risk assessment then 
corresponds to an explicit response level which introduces consistency, but at the same 
time the specifications of suitable levels of response/risk has also shown to be one of 
the main challenges with BMD concept. The NO(A)EL may sometimes be interpreted 
as a dose threshold without adverse health effect. However, as pointed out previously, 
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based on the observed dose-response data the existence of threshold cannot be proven; 
an infinite number of measurements, both in terms of doses and effects, would be 
needed, and such an experiment cannot be conducted from a practical point of view 
(Edler et al. 2002; Slob 1999, 2007). As will be discussed below (section 1.3.1.5) when 
expressing response/risk as defined within the BMD framework (in terms of a BMR), a 
response/risk may also be present at the NO(A)EL in spite of it being a “no-effect 
level”. An extensive discussion and comparison of the BMD and the NOAEL is 
presented in (EFSA 2009a) and in (Sand et al. 2011). 
 
 
Figure 1. A dose-response model fitted to data. The triangles represent the observed mean responses at 
each dose level. The BMD which is a dose corresponding to a predefined change in response is 
determined from the fitted model (solid curve). The dashed lines demonstrate the upper and lower 95% 
confidence bounds for doses corresponding to specified response levels (BMRs). Their intersections with 
the horizontal line result in the lower and upper bounds of the BMD, i.e. BMDL and BMDU respectively. 
In this figure the BMD corresponding to 5% change in response relative to background is illustrated. The 
estimated background level from the fitted model is 8.7 and therefore 5% increase of that equals 9.14 
(8.7+0.05*8.7= 9.14). The BMD of 21.50 is obtained from the intersection of horizontal line at the 
response level of 9.14 with the fitted curve. 
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1.1.3.1 Quantal data and dose-response models 
Quantal data implies data where experimental animals are classified as responders or 
non-responders, e.g. the number of animals with (one or several) tumors in a particular 
dose group. Dose-response data may also be presented in ordinal format. Such data 
result when several sub-classes describing the severity of response (minimal, mild, 
moderate, etc) are defined. The simplest case of ordinal data is equivalent to quantal 
data and, theoretically, as the number of sub-classes in ordinal data approaches infinity, 
continuous data results. It has been discussed that quantal (or ordinal) data may be 
“connected” to an “underlying continuous response”, i.e. when subjects are categorized 
(e.g. by the experimenter) as responders they have exceeded a certain level of the 
“underlying continuous response” (Sand et al. 2008; Slob and Pieters 1998). This type 
of reasoning may however not be applicable to any type of quantal endpoint.  
 
A number of quantal dose-response models have been applied in health risk assessment 
of chemicals (Bailer et al. 2005; Sand et al. 2002). Some of these models are standard 
probability distribution function, such as the (log) logistic, the (log) probit, and the 
Weibull models, and some of them, like the gamma and the multistage models, are 
stochastic models that are based on the assumption that a positive response in an animal 
is the result of random occurrence of one or more biological event (Krewski and Van 
Ryzin 1981). The latter models were previously suggested for assessment of genotoxic 
carcinogens. To date, however, this distinction is not made; models that adequately 
describe the data are further considered in the risk assessment process regardless of 
whether a non-genotoxic or a genotoxic effect is considered. The minimum and 
maximum responses of quantal models are restricted to be in the range of 0 and 100%. 
For quantal data of general type it is assumed that the effect observed for an individual 
is independent of the effect observed for another individual. However, this is not the 
case for developmental toxicity data where fetuses from the same litter may respond 
more similar than fetuses from different litters. For such data intra-litter correlation 
should be regarded. Therefore, specific models and methods have been developed for 
evaluation of developmental toxicity data (Kodell et al. 1991; Kupper et al. 1986; Rai 
and Van Ryzin 1985).   
 
7 
 
1.1.3.2 Continuous data and dose-response models 
For continuous data, the degree of response is observed in the individual subject. 
Enzyme activities, organ weights, and hormone levels are examples of continuous 
responses. A wide range of dose-response models may be used to describe the 
relationship between the dose of chemical and the mean response of a continuous 
endpoint, for example, the polynomial models (including the linear model), the power 
model (Allen et al. 1994a; Allen et al. 1996; Crump 2002; Crump 1984; Crump 1995; 
EFSA 2009a; Kavlock et al. 1995), a family of nested exponential models (Slob 2002), 
and the Hill model family  (Barton et al. 1998; Davis et al. 2011; EFSA 2009a; Gaylor 
and Aylward 2004; Kim et al. 2002; Murrell et al. 1998; Sand et al. 2004; Toyoshiba et 
al. 2004; Zhou et al. 2001). The Hill and exponential families contain a parameter that 
describes the dynamic range of response (the absolute or relative difference between 
the maximum and minimum response levels) that allows the model to plateau at high 
doses. Therefore, these models can produce S-shaped dose-response relationships.  
 
Continuous response data is typically assumed to be normally or log-normally 
distributed. For simplicity, the variance is generally assumed to be constant among dose 
groups. However, this assumption is not always appropriate. For some datasets, the 
variance increases/decreases as the mean response increases/decreases, In such 
situations the variance can be modeled by a statistical function such as power function 
or exponential model (Davis et al. 2011; Sand et al. 2006). In the present thesis, the 
constant model (Papers II and III) and dose-dependent models for variance were 
considered (Papers I and II). 
 
1.1.3.3 Data requirement for BMD modeling 
There are some minimal data requirements for BMD modeling. For quantal data, the 
sample size and the incidence of response is needed for each dose group. For 
continuous data, the observed response data for each experimental animal or the 
summary data (the mean response, the standard deviation, and the number of animals at 
each dose level) are needed. It should be noted that outliers cannot be recognized when 
continuous summary data is used.  
 
In the process of dose-response modeling and BMD analysis it is investigated whether 
or not there is a statistically significant dose-response trend; a BMD is generally not 
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recommended to be derived if no such relationship can be demonstrated. It has been 
debated if a minimal number of dose groups are required for BMD analysis. According 
to U.S. EPA, a dataset should at least contain three dose groups in addition to the 
control group (Davis et al. 2011).  No specific recommendation is given by EFSA. 
Datasets with few dose groups may, depending on dose placement, provide limited 
information on the shape of the dose-response curve. Resulting BMDs and BMDLs 
may then differ substantially depending on the dose-response model used, which 
indicates that a PoD derived from such data will be uncertain. Importantly, applying a 
NO(A)EL approach in such a case is not a better approach. Rather it may be discussed 
if such data are adequate for use in quantitative risk assessment. 
 
1.1.3.4 Selection of dose-response models and overall BMDL 
There are numerous models that may be used to describe the dose-response 
relationships and subsequently drive the BMD. This results in BMD values that are 
model dependent i.e. by fitting different models different BMDs are obtained. To take 
model selection uncertainty into account, it has been suggested that a family of nested 
models such as Hill family or exponential family is fitted to the same dataset (EFSA 
2009a). From each family of models, the model with the appropriate number of 
parameters is then selected, e.g. based on a likelihood ratio test statistic. Considered 
models (e.g. the most appropriate member in each model family) also needs to fulfill 
standard statistical requirements for goodness-of-fit. Visual inspection of the plotted 
dose-response curve can give additional indication of how well the model fits the data. 
There may be cases where the goodness of fit test is violated whereas the model 
appears to fit the data well. There could also be cases where the goodness of fit test 
supports the model while an unrealistic curve fit is observed. 
 
The accepted models are then further considered. Thus, a range of BMDLs may result 
which becomes an indicator of the degree of model uncertainty for the particular data 
set considered (EFSA 2009a). Model averaging approaches have been discussed for 
deriving a single BMDL value from a given dataset (Wheeler and Bailer 2007, 2009), 
but at this point the most conservative (lowest) value is used in practice as the BMDL 
for that particular dataset. The overall PoD is then typically determined, similar as in 
the NOAEL approach, as the lowest BMDL, among the potentially critical 
effects/datasets, in the critical study/s (EFSA 2009a). 
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It should be noted that the proposed models are used descriptively based on some 
general considerations, and are not regarded as biologically based at any detailed level. 
The reliability of the BMD is more related to the quality of the data than the selected 
model. If the data contains sufficient information different models will result in similar 
BMD values (Slob 2002) (“Quality of data” and “sufficient information” here mostly 
refers to the number of dose groups applied).  
 
1.1.3.5 Definitions and specifications of the BMD and BMR 
Depending on the type of response data (quantal or continuous), the BMR associated 
with the BMD is defined differently. For quantal data, the BMR is commonly defined 
in terms of additional or extra risk: 
 
Additional risk: )0()( pBMDpBMR   .  (1) 
Extra risk:   
)0(1
)0()(
p
pBMDpBMR 
 ,  (2) 
 
Where )(BMDp denotes the probability of response at the BMD and )0(p is the 
background probability of response. 
 
For continuous data, several suggestions have been made for how to define the BMD 
(and BMR). The BMD for continuous data has for example been defined as the dose 
corresponding to a percentage change in response relative to background (Crump 1984; 
Slob and Pieters 1998): 
 
)0(
|)0()(|

  BMDBMR   (3) 
 
where )0( denotes the mean background response, and )(BMD denotes the mean 
response at the BMD. The BMR for continuous data has also been presented in terms 
of a change in response relative to the standard deviation of the control group, σ(0) 
(Crump 1984; Crump 1995; Kavlock et al. 1995); 
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)0(
|)0()(|

  BMDBMR   (4) 
 
In addition to the definitions presented above the BMD has alternatively been 
expressed as the dose corresponding to a change in response relative to the estimated 
dynamic range of response (the difference of the maximum and minimum response 
levels) (Murrell et al. 1998): 
  
)min()max(
|)0()(|
responseresponse
BMDBMR 
    (5) 
 
This definition is only applicable in situations where the model describing the dose-
response data levels off to some limiting value, i.e. consist of a parameter that describes 
the dynamic range of response.  
 
Observe that for quantal data the BMD corresponds to a change in the probability of 
response, while no probability based interpretation can (directly) be made for the 
BMD/BMR definitions discussed above for continuous data. However, an indirect 
probability based method has also been presented for continuous data (Crump 2002; 
Crump 1995; Gaylor and Slikker 1990), which has mostly been applied to 
epidemiological data in practice (Budtz-Jorgensen et al. 2000; Clewell et al. 2003; 
Jacobson et al. 2002). In this approach, a probability model that describes the 
proportion of the distribution (describing the variability in the population) below (or 
above) a specific cut-off value as a function of dose is estimated. The BMD is the dose 
where the probability of exceeding (or falling below) the cut-off level has increased by 
a particular percentage according to the additional or extra risk definition (equations 1 
and 2). BMDs calculated for continuous endpoints according to this approach have 
probability based interpretation in similarity to BMDs derived from quantal data. 
 
A critical issue concerns the specification of the BMR value in BMD analysis. The 
BMR should ideally be based on toxicological considerations (e.g. represent a non-
adverse effect size). However, it should not be set at levels outside the range of 
observed responses. Extrapolation far beyond the range of the data can result in BMDs 
which become dramatically different depending on the model used (EFSA 2009a). 
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Default values for the BMR for quantal and continuous data have been suggested; 
however the selection of other BMRs can be justified with biological and statistical 
considerations. 
 
For quantal data, U.S. EPA and EFSA have suggested a BMR of 10% as default, 
defined in terms of extra risk (Davis et al. 2011; EFSA 2009a). Some studies have 
compared NOAEL and BMDL values across several datasets to address the issue of 
suitable BMR levels. Results from those studies suggest that the risk at NOAEL 
corresponds to a BMR level in the range of 5-10% or more than 10% (Allen et al. 
1994a, 1994b; Fowles et al. 1999). More recently, dose-response analysis of 786 
dataset from the U.S. National Toxicology Program Carcinogenesis Bioassay Program 
indicated that the upper bound on extra risk at the NOAEL was close to 10% at median 
(Sand et al. 2011). Hence, while the NOAEL does not correspond to a statistically 
significant change in risk (or effect), a risk at the NOAEL is apparent in terms of BMR 
and depends on the dataset considered.  
 
In Sand et al (2011) the issue of BMR for quantal data was further addressed by the 
definition of a signal-to-noise crossover dose (SNCD). The SNCD is the dose at which 
the additional risk is equal to some fraction of background noise. The SNCD was 
discussed as an objective estimate of the lowest dose applicable as a PoD for a 
particular dataset, without having the signal (i.e. the point estimate of additional risk at 
a certain dose, d) overwhelmed by noise (i.e. the difference between the upper and 
lower bound of a two-sided 90% confidence interval on absolute risk at the same dose, 
d). 
 
For continuous data, EFSA recommends a BMR of 5% as default; defined as a 5% 
change in the mean response relative to the background mean response. EFSA states 
that a 5% response is often within the range of observation, and would provide BMDL 
estimates that are not critically dependent on the dose-response model. A re-analysis of 
a large number of U.S. National Toxicology Program studies showed that the BMDL05 
was, on average, close to the NOAEL derived for the same dataset, while in most 
individual datasets they differed within one order of a magnitude (EFSA 2009a). 
 
The data evaluated in the present thesis is continuous, and the BMD was defined as the 
dose corresponding to 5%, 10% and 100% (depending on the endpoint considered) 
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change in response according to Equation 3 (Papers I, II,  III and IV) and Equation 5 
(Paper I). 
 
1.1.3.6 Human dose-response data 
The definitions of BMD for quantal and continuous data discussed above are dependent 
on the response level in unexposed subjects. However, many epidemiological studies 
may not include an unexposed control group and therefore application of the BMD 
method may be problematic. In this situation a model can still be fitted to the data since 
fitting a dose-response model does not necessarily require observations at the control 
group. The response in the unexposed group can be determined by low-dose 
extrapolation, but it is important to note that a BMD derived in such a case may 
become highly model-dependent (Budtz-Jorgensen et al. 2001; EFSA 2009a). 
Furthermore, epidemiological studies involve different sources of uncertainty that may 
lead to a biased estimate of the BMD. In order to obtain less biased estimates, factors 
such as imprecision in human exposure, confounders and effect modifiers need to be 
handled by suitable statistical methods or by including them in the model as covariates 
(Budtz-Jorgensen et al. 2004; EFSA 2009b). 
 
1.1.3.7 Comparison of dose-response relationships 
An important issue in risk assessment is to assess the relative potency between different 
chemicals or relative differences in sensitivity between subpopulations (e.g. animal 
strains, sexes or species). Such a comparison can be performed by introducing a 
covariate/s in the model. It is then possible to investigate whether the dose-response 
relationships of two sub-populations are similar or not, i.e. are the sub-populations 
equally sensitive or not. Comparison of dose-response curves in the context of BMD 
analysis and risk assessment has generally been discussed by (Slob 2002). In Papers I 
and II, a framework was developed for assessing quantitative and statistical differences 
in sensitivity following chemical exposure, and in Paper III, relative potency (REP) 
values for a group of polychlorinated biphenyls (PCBs) were estimated. 
 
1.1.3.8 Study design 
The question whether or not the typical study designs used in animal experiments are 
adequate for BMD analysis, and/or what the optimal design is for estimating the BMD 
has been discussed in a few studies. Slob et al. (2005) studied this for continuous data 
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considering the BMD defined as the dose corresponding to 5% change in response 
relative to background. It was concluded that the performance of a design is determined 
by the total number of animals, and increasing the number of dose groups while 
reducing the number of animals per dose group, does not result in poorer performance 
of the design. In addition to the sample size, the dose placement showed to be an 
important factor and to minimize the risk of inadequate dose placement, studies with 
multiple dose levels are favorable (Slob et al. 2005). Investigations have also been 
made for continuous data by Kuljus et al. (2006) considering the Hill model where the 
BMD was defined as a change in response relative to the dynamic range of response 
(equation 5). The main purpose of this study was to investigate the effect of increasing 
the number of dose groups and at the same time decreasing the number of animals per 
dose group. The results suggested that to avoid unfavorable dose placement, studies 
should be designed with more than four dose groups. To further improve the study 
design any prior information about the dose-response relationship, e.g. information 
from similar previous studies should also be taken into account (Kuljus et al. 2006). 
 
1.1.4  Extrapolation factors 
1.1.4.1 Interspecies and Intraspecies extrapolation 
The PoD derived from experimental or epidemiological studies cannot directly be used 
to set an RfD for the human population. To establish the RfD, the PoD is commonly 
divided by one or more extrapolation factors (EFs) depending on the characteristics of 
the study (e.g. animal study or human study) used for derivation of the PoD.  
 
In the mid-1950s, an assessment factor of 100 was introduced in the United States by 
the Food and Drug Administration for deriving safe exposure levels for food additives.  
This approach was later modified slightly and applied by U.S. EPA in setting RfDs for 
environmental pollutants (Falk-Filipsson et al. 2007). Although it is hard to find a firm 
scientific basis for a 100-fold assessment factor, it is generally considered to consist of 
a 10-fold EF for describing interspecies differences and a 10-fold EF for describing 
intraspecies differences. The default interspecies EF of 10 is intended to account for the 
difference between the average experimental animal and the average human, and the 
default intraspecies EF allows extrapolating from the average to the sensitive human. 
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In an attempt to replace default EFs with data-derived EFs by incorporation of 
mechanistic information, Renwick (1993) subdivided each of 10-fold EFs into a 
toxicokinetic factor of 4 and a toxicodynamic factor of 2.5. A more flexible framework 
that develops a series of EFs related to different processes of metabolism and excretion 
when chemical-specific toxicokinetic or toxicodynamic data are not available has also 
been proposed (Dorne et al. 2001, 2004; Renwick et al. 2000; Walton et al. 2004).  
 
Several authors have suggested data-based empirical distributions for inter- and 
intraspecies factors (Edler et al. 2002; Price et al. 1997; Slob and Pieters 1998; 
Swartout et al. 1998; van der Voet and Slob 2007; Vermeire et al. 1999). Most of these 
distributions are based on ratios of NOAEL values from different studies (for the same 
compounds). As an alternative, Bokkers and Slob (2007) have proposed an empirical 
data-based interspecies EF distribution based on the BMD ratio of mouse and rat 
studies. van der Voet and Slob (2007) suggested that the EF interspecies factor can be 
described by a log-normal distribution with geometric mean (GM) equal to 4 and a 
geometric standard deviation (GSD) equal to 1.48. Under these settings the 99th 
percentile of the log-normal distribution is equal to the default interspecies factor of 10. 
To describe the intraspecies EF distribution van der Voet and Slob (2007) combined 
both variability and uncertainty. They assumed that the variability among individuals in 
the population is log-normally distributed with GM of 1 and a GSD which has a chi-
square distribution. The log-normal distribution reflects variability while distribution 
for the GSD reflects the uncertainty of this variability. The degrees of freedom for the 
chi-square distribution was specified such that the default intraspecies factor of 10 
equals the 99th percentile of the resulting intraspecies (log-normal) distribution (van der 
Voet and Slob 2007). In the present thesis, the inter- and intraspecies EF distributions 
proposed by van der Voet and Slob (2007) were considered (Paper IV). 
 
1.1.4.2 Sub-chronic to chronic extrapolation 
The most relevant experimental exposure duration to be used as basis for establishment 
of the RfD is chronic exposure, since these health-based guidance values should protect 
the human population from adverse health effects of chemical substances after life-long 
exposure. However such data may not always be available. By default, a factor of 10 is 
applied to for sub-chronic to chronic extrapolation. A data-based EF has been 
suggested, by considering a certain percentile of the sub-chronic to chronic NOAEL 
ratio distribution (Pieters et al. 1998). Instead of using ratios of NOAELs, Bookers and 
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Slob (2005), derived a data-based EF distribution by estimating BMD ratios for sub-
chronic and chronic studies (body weight and liver weight data on mice and rats). They 
proposed a lognormal distribution with a GM of 1.7 and GSD of 2.9 to describe the 
sub-chronic to chronic EF (Bokkers and Slob 2005). In this thesis, the latter sub-
chronic to chronic EF distribution was considered (Paper IV). 
 
1.1.5 Establishment of health-based guidance value 
Traditionally, the RfD is established by dividing a deterministic PoD by various point 
estimates of EFs. As an alternative, a probabilistic approach may be applied. In this 
case bootstrap procedures may be used to assess the uncertainty in the BMD (the 
complete BMD distribution is considered as the PoD). The uncertainty distribution of 
the BMD is then divided by the distributions for different EFs (as discussed above) to 
derive an uncertainty distribution for the RfD for the sensitive human (Slob and Pieters 
1998; van der Voet and Slob 2007): 
 
ࡾࢌࡰ࢙ࢋ࢔࢙࢏࢚࢏࢜ࢋࢊ࢏࢙࢚࢘࢏࢈.ൌ ࡮ࡹࡰࢊ࢏࢙࢚࢘࢏࢈࢛࢚࢏࢕࢔ࡱࡲ૚ࢊ࢏࢙࢚࢘࢏࢈.ൈࡱࡲ૛ࢊ࢏࢙࢚࢘࢏࢈.ൈ…ൈࡱࡲ࢏ࢊ࢏࢙࢚࢘࢏࢈.     (6) 
 
To date a probabilistic approach for establishing human exposure guidelines has not 
been applied in risk assessments in practice. 
 
It should be kept in mind that treating the RfD as a definite level, and considering 
exposures above the guideline as being associated with a health risk can be misleading. 
More informative indications of  both severity and frequency of health effects that may 
occur in an exposed population should instead be provided (Clewell and Crump 2005). 
 
1.2 EXPOSURE ASSESSMENT 
1.2.1 Deterministic and probabilistic methods 
Human exposure to chemicals occurs as a result of inhaling air, drinking water, eating 
food, or through dermal contact with products that contain the chemical. For 
assessment of dietary exposure, information of consumption habits and chemical 
occurrence in foods are needed. Food consumption data is obtained from consumption 
surveys in the population, and the concentration of chemicals in different food items are 
e.g. derived from food monitoring programs. If the consumption data concern foods as 
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eaten (i.e. pancakes) while the concentration data is available only for the raw foods 
(i.e. egg), information on recipes and food processing is ideally needed to match the 
consumption and concentration data. 
 
Human exposure assessment can be performed using different methodologies. 
Routinely, a deterministic approach is applied by combining point estimates of food 
consumption with point estimates of concentrations of chemicals in corresponding food 
items. This approach regards only a single consumption scenario and assumes a 
constant concentration of chemicals present in the food. In order to protect the majority 
of the population worst case scenario approaches may be applied by using conservative 
estimates of the input parameters, i.e. the 95th/99th percentile or the maximum value 
may be considered (Kroes et al. 2002). This type of deterministic approach may be 
applicable as a primary step for evaluating the exposure situation. However, if a risk 
cannot be excluded under such an assessment a more realistic approach is required as a 
higher tier to judge whether or not the exposure may be associated with adverse health 
effects (Bosgra et al. 2009). 
 
In contrast to the deterministic approach, the probabilistic analysis accounts for both 
variability (due to variation between individuals in food consumption and variability 
between concentrations of chemicals in the consumed foods) and uncertainty. Hence, 
this approach results in a more realistic illustration of health risk that can occur in the 
population. This approach employs all available information and allows us to avoid 
choosing worst case estimates for input parameters (Bosgra et al. 2005; Kroes et al. 
2002; van der Voet and Slob 2007). Variability and uncertainty should be treated 
separately. Variability between individuals in exposure to chemicals is evaluated by 
Monte Carlo simulations. Bootstrap simulations can be used to assess the uncertainty; 
random values are drawn directly from the input data (non-parametric bootstrapping) or 
from probability distributions describing the input data (parametric bootstrapping). 
Uncertainty distributions with respect to different percentiles of the exposure can be 
obtained since the exposure is evaluated for several bootstrap samples. While 
probabilistic modeling confers many advantages, in order to create reliable input 
distributions sufficient data on input parameters is needed (Kroes et al. 2002). 
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1.2.2 Cumulative exposure 
Health risks related to chemical exposures are mostly assessed separately for each 
compound whereas in reality humans are exposed to a complex mixture of chemicals 
(Kortenkamp 2007). Despite the recognition of this problem for decades, there are only 
a few models for prediction of cumulative exposure to chemical mixtures. The TEF-
system proposed by WHO is the most common method to characterize the toxicity of 
human exposure to dioxins and dioxin-like (DL) compounds (Van den Berg et al. 
2006). For pesticides, the relative potency factor (RPF) approach has been developed 
(Boobis et al. 2008; Muller et al. 2009; USEPA 2000), and this approach has also been 
applied for PAHs (Pufulete et al. 2004). Both the TEF and RPF approaches are based 
on selecting a reference compound and assessing the potency of other relevant 
compounds in relation to this reference. In the RPF approach, the cumulative exposure 
of the relevant compounds is then expressed in terms of reference compound 
equivalents, which are obtained by normalizing the exposure of each substance with its 
RPF. The RPF and TEF approaches are based on the assumption that there are no 
interactions between the considered chemicals; if the chemicals interact so that effects 
are modulated, information for the individual chemicals is not sufficient for predicting 
their combined effect. 
 
TEFs are determined based on a scientific judgment of multiple REP values from 
different studies for multiple endpoints. A set of criteria was developed to determine 
the REP values that can be included in the WHO TEF system. In order to assign a TEF 
value to a compound it should have a chemical structure that is similar to that of 
polychlorinated dibenzo-p-dioxins (PCDD) or polychlorinated dibenzofurans (PCDFs), 
bind to aryl hydrocarbon receptor (AhR), and show AhR mediated biochemical and 
toxic responses. The compound should also be persistent and accumulate in the food 
chain (Ahlborg et al. 1994; Van den Berg et al. 2006). The RPF method can be used 
when a class of compounds appears to share a common mode of action; however, the 
exact mechanism is complex and may not be known in detail (USEPA 2000).    
 
Several groups of compounds cannot be included in the TEF system as they do not 
fulfill the criteria of binding to AhR, although they have similar effect as the DL 
compounds on an endpoint basis. Therefore, when estimating the combined effect by 
only focusing on TEF assigned compounds, which have similar mechanism of action, 
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and not including the potency of other compounds with similar effects, the combined 
effect of mixtures might be underestimated. Hence, developing endpoint-specific RPF 
databases for endpoints that are observed after exposure to compounds with and 
without assigned TEFs seems to be appropriate (Ahlborg et al. 1994). When applying 
the RPF approach for estimating the cumulative exposure, one should bear in mind that 
the RPFs can be applied for the endpoints for which they were obtained and not for all 
endpoint (Muller et al. 2009). 
 
1.3 RISK CHARACTERIZATION 
The purpose of risk management is to protect the population from the adverse effect of 
chemicals. Advice to risk manager about the nature and magnitude of risk from 
exposure to chemicals can be given in a quantitative or qualitative form. Integrating 
exposure assessment and hazard characterization into risk characterization is an 
important step in risk assessment (Renwick et al. 2003).  
 
Normally, a deterministic approach is used at the level of risk characterization. A 
margin of exposure (MOE) or margin of safety (MOS) may be established by 
comparing a PoD like the NOAEL or BMDL with the mean/median or some percentile 
of the estimated human exposure. The MOE and MOS may be considered equivalent 
terms (IPCS 2004; sometimes the MOS is used when the health-based guidance value 
is applied as reference instead of the NOAEL or BMDL). For genotoxic carcinogens 
quantitative estimates of cancer risk at given exposure (using linear extrapolation 
models) have traditionally been performed by the WHO and the U.S. EPA. EFSA 
proposed a MOE approach for risk assessment of compounds that are both genotoxic 
and carcinogenic; the MOE is here defined as the ratio between the BMDL, obtained 
from animal dose-response data for the critical effect, and a point estimate of the 
human exposure (EFSA 2005). 
 
When appropriate data are available risk characterization may be carried out by 
probabilistic modeling. Such approaches have so far mostly been discussed at the level 
of the exposure assessment domain. The probabilistic approaches have not yet been 
used to aid the risk characterization or at the level of the hazard characterization 
domain in practice, e.g. for establishing health-based guidance values. A probabilistic 
MOE approach has been presented by van der Voet and Slob (2007). This is an 
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integration of the probabilistic approaches already described in this thesis at the level of 
hazard characterization and exposure assessment; it account for both variability and 
uncertainty in the estimation of the MOE. In Paper IV of current thesis, the model 
proposed by van der Voet and Slob (2007) was extended and refined to estimate the 
cumulative MOE for a group of PCBs using vitamin A as an example endpoint. 
Selected percentiles of the MOE distribution can be used to characterize the proportion 
of the population that can be considered to be at risk (Bosgra et al. 2009; van der Voet 
and Slob 2007; van der Voet et al. 2009). 
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2 PRESENT INVESTIGATION 
 
2.1 AIM 
The general objective of this thesis relates to development of methods applied for 
quantitative health risk assessment of chemical substances. The focus can be divided in 
two parts: 
 
In part one the objective was to further develop and promote approaches for 
comparison of dose-response relationships for estimating 1) differences in sensitivity 
between sub-populations, and 2) differences in potencies between chemical substances. 
The specific project objectives were: 
 
 To estimate the relative difference in sensitivity between L-E and H/W rat 
strains (with different AhR structure) considering a number of conventional 
toxicological endpoints as well as endocrine system relevant changes in tissue 
retinoid levels (Paper I). 
 To estimate the relative difference in sensitivity between L-E and H/W rat 
strains for changes in bone geometry, mineral density and biomechanical 
properties (Paper II).  
 To estimate REP values for a group of DL and non-dioxin-like (NDL) PCB 
congeners with the application of traditional approaches, i.e. using the ratio 
between NO(A)ELs/LO(A)ELs or median effective doses (ED50s), and a new 
approach, i.e. using the ratio between BMDs (Paper III).  
  
In part two the objective was to evaluate and further develop a generalized MOE 
approach for risk characterization of chemical mixtures by integrating dose-response 
modeling based on experimental effect data and exposure modeling based on human 
consumption data. The specific project objective was:   
 
 To implement and evaluate an approach for estimating the cumulative MOE, 
with and without incorporation of RPFs, considering a group of DL and NDL 
PCBs (Paper IV). 
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2.2 MATERIALS AND METHODS 
 
2.2.1 Data 
2.2.1.1 Dose-response animal data 
Some of the animal dose-response data used in this thesis were generated in our lab and 
some were obtained from scientific collaboration (Papers I and II) or derived from the 
literature (Papers III and IV). The dose-response data used was continuous in nature, 
describing the degree of severity of effect at the level of individual animals. 
 
For Papers I and II, dose-response data on body and organ weights, altered hepatic 
foci, hepatic ethoxyresorufin-O-deethylase (EROD) activity, as well as retinoid and 
bone parameters, observed in female Long-Evans (L-E) and Hans/Wistar (H/W) rats 
following long-term exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was 
used.  
 
In Papers III and IV dose-response data on post-mortem observations, including gross 
changes such as fatty liver and spleen enlargement, organ weight, biochemical changes, 
tissue vitamin A levels, hematological changes such as anemia, etc, was derived from 
previously published studies (Chu et al. 2000; Chu et al. 1998; Chu et al. 1995; Chu et 
al. 1994; Chu et al. 1996a; Chu et al. 1996b; Lecavalier et al. 1997).  
 
2.2.1.2 Human exposure data 
For estimating the human dietary exposure, food consumption data and data on 
chemical concentrations in food was obtained by collaboration with the Swedish 
National Food Agency (NFA) (Paper IV). Data from the food consumption survey 
conducted by the NFA in collaboration with the Swedish Statistical Agency in 1997-
1998, on adult men and women (Riksmaten 97-98) was used (Becker and Pearson 
2002).  The concentration data on PCBs in food originates from the NFA dioxin control 
program from 2003 and onwards, and from NFA food monitoring studies from 1999 
and onwards. The concentration data for each PCB congener was extrapolated to the 
year 2009 with a 3.3 – 8.6 % decrease per year depending on the congener. 
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2.2.2 Dose-response assessment 
2.2.2.1 Assumptions and model fitting 
In Papers I, II and III data from two different sub-populations (Papers I and II) or 
two different compounds (Paper III) were analyzed simultaneously.  Data was 
assumed to be normally distributed. The log-likelihood function can then be written as: 
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where N is the total number of animals; gi is the number of dose groups for dataset i; ijn  
is the number of animals in the j’th dose group of dataset i; and 2ijs and ijy  are unbiased 
sample variance and the sample mean response in the j’th dose group for dataset i, 
respectively. The parameters defining the mean response )( ijd  and the variance 
 ijd2  are estimated by maximizing the log-likelihood. 
 
In Papers III and IV, data was assumed to be log-normally distributed. However, 
equation 7 still applies since the response data was log-transformed before analysis. It 
should be noted, however, that in this case the estimated dose-response models describe 
the mean of the log-transformed response.  
 
In Papers I and II equation 7 was used for fitting a model to dose-response data on L-E 
and H/W rats simultaneously (for a given endpoint), while in Paper III it was used for 
fitting a model to dose-response data on PCB 126 and another PCB congener 
simultaneously (for a given endpoint). In Paper III, the log-likelihood function was 
also further extended so that a model was fitted to both the male and female dose-
response data for PCB 126 and another PCB simultaneously (for a given endpoint). In 
Paper IV, models were fitted to dose-response data on individual PCB congeners 
separately i.e. using equation 7, without summing over several datasets.  
 
2.2.2.2 One way analysis of variance (ANOVA) 
In Papers II and III in order to determine NO(A)ELs and LO(A)ELs, one-way 
ANOVA followed by Dunett’s  post-hoc test (Paper II) and pairwise t-test (Paper III) 
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was used to compare different dose groups against the corresponding control group at a 
significance level equal to 0.05.  
 
2.2.2.3 Dose-response models 
In all papers, the model used for analyzing the dose-response data was the Hill 
function, which in its general form can be written as: 

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
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dd )(  ,                           (8) 
                         
where   is a parameter that describes the background response; k is the location 
parameter (which equals the ED50 dose);   is a parameter that describes the shape of 
the dose response curve;   is a parameter that describes the dynamic range of 
response (the difference between the estimated maximum and minimum response 
levels); and where id  is the dose administered to the i’th treatment group. If   equals 
1, the Hill function coincides with the Michael-Menten equation. These two models are 
nested and therefore it was tested if the data could just as well be described by the 
Michael-Menten equation which is a simpler model. The variance was assumed to be 
constant among dose groups, c2 . In Papers I and II, in addition to the constant 
model, a dose dependent exponential model, )1ln(2  de  , was also considered 
for the variance. 
 
2.2.2.4 Likelihood ratio test 
The likelihood ratio test was used to assess individual model fit and for selecting the 
most appropriate model in a family of nested models. It can be shown that twice the 
difference of the log-likelihoods associated with the two models approximately follows 
a chi-square distribution with the degrees of freedom equal to the difference in the 
number of parameters between the two models. In addition, this test is the basis for the 
likelihood profile method, which was used to estimate the confidence interval for the 
BMD ratios in Papers I, II and III. 
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2.2.2.5 RfD distribution 
In Paper IV, an approach for estimating an RfD under a probabilistic framework was 
applied. A “new” dose-response dataset was generated using a parametric bootstrap 
procedure. The BMD resulting from fitting a selected Hill model to the new dataset was 
divided by an interspecies extrapolation factor (EFinter) that was drawn from log-normal 
distribution (with GM= 4 and GSD = 1.48) . The resulting value was divided by 20 000 
random values drawn from an intraspecies extrapolation distribution (EFintra) 
corresponding to a log-normal distribution (with GM = 1 and GSD = 25598.1  ) 
where 25 is a random value draw from a Chi-square distribution (with five degrees of 
freedom) (van der Voet and Slob 2007). This results in an RfD distribution describing 
variability among individuals. The RfD distribution was also divided by an additional 
factor to account for subchronic to chronic extrapolation; this factor was randomly 
drawn from a lognormal distribution (with GM = 1.7 and GSD = 2.3) (Bokkers and 
Slob 2005). In order to evaluate the uncertainty in the RfD distribution the process 
described above was repeated for 500 times. 
 
2.2.3  Exposure assessment 
In Paper IV, the human dietary exposure to single PCB congeners, as well as the 
cumulative exposure for a whole group of PCBs was estimated. 
 
A non-parametric bootstrap sample was drawn with replacement from the consumption 
data, with respect to individuals in the consumption survey (Riksmaten 97-98). 
Similarly, a non-parametric bootstrap sample was drawn with replacement from 
concentration data, with respect to each food item (correlation between compounds for 
each food item was accounted for in this process). A mean concentration was estimated 
with regard to each food category for each PCB congener. For all individuals in the 
consumption survey, the (average) daily body weight-adjusted dietary exposure over all 
food groups was estimated with regard to each PCB congener. To assess the 
uncertainty in the estimated exposures, the procedure described above was repeated 500 
times. 
 
For assessing the cumulative exposure, RPFs estimated for the PCBs in Paper III (using 
PCB 126 as the reference compound) were used. The RPFs were assumed to have a 
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log-normal distribution with GM equal to the RPF point estimate. The GSD of this 
distribution was estimated from the two-sided confidence interval for the RPF. In each 
uncertainty round, the estimated exposure for each PCB congener (described above) 
was multiplied by a random value drawn from the respective PCB-specific RPF 
distribution. The cumulative exposure was then estimated as the sum of the adjusted 
exposures (in terms of PCB 126 equivalents) of all PCBs.  
 
2.2.4 Margin of exposure 
In Paper IV, the cumulative MOE was estimated. This was performed with and 
without the incorporation of RPFs. In the RPF-based approach, the cumulative MOE 
was calculated as the ratio between the RfD distribution (based on 20 000 values) for 
PCB 126 and the cumulative dietary exposure distribution (20 000 values were 
randomly generated from a fitted log normal model) expressed in terms of PCB 126 
equivalents. In the RPF-free approach, PCB-specific MOEs were estimated as the ratio 
between the PCB-specific RfD distribution and the PCB specific dietary exposure 
distribution.  The inverse of the PCB-specific MOEs were summed, and the cumulative 
MOE was calculated as the inverse of this sum. Figures 2A and 2B describe the 
procedure to derive the RPF-based cumulative MOE. 
 
 
 
Figure 2A. Animal toxicity data for PCB126 (male rats) was analyzed using the BMD approach. The 
BMD was divided by extrapolation factors, EFinter, EFintra and EFsubchronic-chronic, by Monte Carlo 
simulations, resulting in a distribution for the RfD. To account for uncertainties, the process of estimating 
the RfD was repeated, n = 500 times.  
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Figure 2B.  The distribution for the cumulative exposure (expressed in terms of the PCB126 equivalents) 
is obtained by 1) combining consumption amounts and average PCB concentrations for each food group; 
2) adjusting the total exposure for each PCB by applying the appropriate RPF, and 3) summing adjusted 
exposures over all PCB congeners. The distribution of the cumulative MOE is the ratio between the RfD 
distribution and the cumulative exposure distribution, obtained by Monte Carlo simulations. To account 
for uncertainties, the process of estimating the cumulative MOE was repeated, n = 500 times. 
 
2.2.5 Software 
The mathematical and statistical procedures applied in this thesis were developed in 
Matlab (version 7.0).  
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 Comparison of dose-response relationships 
2.3.1.1 Strain differences in sensitivity 
The differences in sensitivity between two strains, species or the difference in potency 
of two chemicals is traditionally assessed by the comparison of their corresponding 
NO(A)ELs (LO(A)ELs) or ED50s. As has been discussed previously, a NO(A)EL 
depends heavily on the study setup and therefore it is regarded to contain substantial 
error. This error becomes even larger for the NO(A)ELs ratio. Whereas, the BMD is 
derived by using the whole data and it is expected to be more informative compared to 
the NO(A)EL. 
  
In Papers I and II, differences in sensitivity between L–E (dioxin sensitive) and H/W 
(dioxin resistant) rats following long-term exposure to TCDD were quantitatively 
investigated. Although the effects of dioxin exposure in the two rat strains has been 
extensively studied before, this was the first time a detailed statistical analysis was 
employed to quantify the relative difference in sensitivity between the two strains 
following long-term TCDD exposure. 
 
In Paper I, the difference in sensitivity between L-E and H/W rats was investigated for 
a variety of toxicological endpoints including data on body and organ weights, hepatic 
foci, hepatic CYP1A1 induction, as well as tissue retinoid levels. For a given endpoint, 
the BMDs for L-E and H/W rats were estimated by the Hill function that was fitted to 
the dose-response data. In Paper I, the BMD derived for every endpoint was defined as 
the dose corresponding to a percentage change in response relative to background 
response as well as a percentage change in response relative to the range between 
maximum and background response (equations 3 and 5). The sensitivity difference was 
then estimated in terms of a BMD ratio, i.e. BMDH/W/BMDL-E. The BMD ratio 
becomes a constant value that is independent of the BMR level used in the BMD 
calculation when the dose-response models are parallel, i.e. when the two curves have 
the same dose-response shapes, but the location of the curves on the dose scale may 
still differ. The BMD ratio becomes dependent on the selected BMR level when the 
dose-response curves are not parallel. The BMD ratio confidence interval reflecting the 
uncertainty in the sensitivity difference was also estimated. If this confidence interval 
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contained the value 1, the two strains were not regarded to differ statistically in their 
sensitivity to dioxin exposure.    
 
The statistical analysis demonstrated that the assumption of parallel dose-response 
curves was accepted for most of the parameters investigated. The parallel curve 
assumption was rejected for the data on volume fraction of hepatic foci, and hepatic 
retinyl palmitate, and hence for these endpoints the BMD ratio is not constant. A 
range of BMRs were therefore employed for calculating the BMD ratio for these 
endpoints.  
 
It was concluded that L-E and H/W rats differed statistically in their response to 
TCDD treatment for most of the parameters investigated in this study, i.e. the 
confidence interval corresponding to the BMDH/W/BMDL-E ratio did generally not 
include a BMD ratio = 1. Differences in response between the strains were most 
pronounced for hepatic foci; L-E rats were approximately 20-40 times more sensitive 
than H/W rats. For body and organ weight parameters, L-E rats were approximately 
10-20 times more sensitive than H/W rats. For retinoid parameters and hepatic 
CYP1A1 induction, estimated differences between the strains were generally about 5-
fold, and associated with a low uncertainty (Paper I, Table 2). The dose-response 
model and profile likelihood curve generated for thymus weight data are shown in 
Figures 3A and 3B. 
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Figure 3A. The Hill function fitted to data on thymus weight observed in L-E (triangles) and H/W 
(circles) rats following long-term TCDD exposure. The point estimate of the BMD ratio presenting the 
strain difference in sensitivity to TCDD exposure is 11. The BMD is defined as a dose corresponding 
to 5% change in response relative to background. However, as the dose-response curves could be 
assumed to be parallel the BMD ratio is independent of the BMR level selected.  
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Figure 3B. Establishment of a confidence interval for the BMD ratio using the profile likelihood method. 
The 90% confidence interval for the BMD ratio was estimated to 4.1 - 23.6. Since the confidence interval 
does not include a BMR ratio = 1, the two strain are considered to differ statistically in their sensitivity to 
TCDD exposure. 
 
 
In Paper II, data on bone geometry, mineral density and biomechanical properties that 
were derived from the same toxicity study as presented in Paper I were considered.  In 
this investigation, for every endpoint, the BMD and BMDL were estimated and 
compared to the associated NOAEL value. The relative difference in sensitivity 
between L-E and H/W rat strains, in terms of the ratio between their corresponding 
BMDs, was also investigated for bone parameters where both strains showed 
statistically significant effects. The BMD was defined as corresponding to the default 
BMR level of 5% change in response relative to background, according to equation 3. 
In order to assess the influence of BMR level on the results, additional calculations 
were also performed considering a BMR level equal to a 10% change in response 
relative to background. 
 
The results in Paper II indicated that the BMD approach is a more suitable method 
for evaluation of bone parameters compared to the NOAEL method. For a few 
endpoints, NOAEL values could not be established whereas the corresponding BMDs 
could be identified. For the cases where a NOAEL value could be derived, it was in 
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the same range as the BMDL corresponding to a 5% response. This indicates that 
despite the assumption that NOAEL is considered as a risk/effect-free dose, it does in 
fact correspond to an unknown effect size. The effect size associated with BMD, on 
the other hand, is explicitly presented which may be considered to result in more 
transparent risk assessments. BMDLs corresponding to a response level of 10% were 
for most parameters higher than the corresponding NOAELs and 2-10 times higher 
than BMDLs corresponding to a response level of 5%. In overall, a response level of 
5% seems to be relevant for the estimation of BMDs and BMDLs corresponding to 
the different bone parameters that were investigated in Paper II.  
  
For those bone parameters where both strains showed a significant dose-response 
relationship, strain sensitivity differences were estimated by comparing their 
corresponding dose-response relationship as illustrated for data on cross sectional 
area of proximal tibia in Figure 4. For these nine parameters, the dose-response 
curves of L-E and H/W rats could be assumed to be parallel according to the 
likelihood ratio test; there was a 10-fold strain difference for energy absorption of 
proximal tibia and length of tibia, and a 49-fold difference for cross-sectional area of 
proximal tibia (Figure 4), while there was no statistically significant strain difference 
with respect to the other six parameters (Paper II, Table 6).  It should be born in mind 
that for some parameters there was no observed effect for H/W rats and therefore 
taken all endpoints together the data suggest a significant difference in sensitivity 
between two strains with the L-E rat being the most sensitive strain. This finding 
provides support for the distinct role of AhR for the effects of TCDD on adult bone. 
The results obtained in Paper II provide new quantitative information about TCDD-
induced bone alterations at doses which are of relevance from a health risk 
assessment point of view and suggest that the BMD approach is an appropriate 
method for such evaluation. 
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Figure 4. The Michael-Menten equation fitted to data on cross-sectional area of proximal tibia 
observed in L-E (circles) and H/W (triangles) rats following long-term TCDD exposure. The point 
estimate of the BMD ratio presenting the strain difference in sensitivity to TCDD exposure is 49. The 
BMD is defined as a dose corresponding to 5% change in response relative to background. However, 
as the dose-response curves could be assumed to be parallel the BMD ratio is independent of the BMR 
level selected.  
 
2.3.1.2 Establishment of relative potency values 
In Paper III,  REP values for individual PCB congeners compared to PCB 126 (as the 
reference compound) were established using traditional approaches, i.e. as the ratio 
between NO(A)ELs/LO(A)ELs or median effective doses (ED50s), and a more recent 
approach, i.e. as the ratio between BMDs. Data on male and female rats from a series of 
single compound experiments including DL PCBs 77, 105, 118 and 126 (included in 
WHO-TEF concept), as well as NDL PCBs 28, 128 and 153 (not included in the WHO-
TEF concept) was evaluated. Increased liver weight, decreased hepatic vitamin A, and 
hepatic EROD induction were the endpoints considered for this evaluation. Increased 
liver weight is a well-established organohalogen endpoint. Although alterations in 
hepatic vitamin A and hepatic EROD activity may not be toxic per se, hepatic vitamin 
A reduction can be considered as a sensitive indicator of an altered retinoid 
homeostasis, and induction of EROD activity is indicative of AhR activation. 
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The BMR associated with the BMD was defined as a percent change in response 
relative to the background (equation 3). The BMR level was specified to a 5% change 
for hepatic vitamin A and relative liver weight data, and a 100% change for hepatic 
EROD activity data. In Paper III, the data was analyzed on the log-response scale. The 
discussed response changes above concerns the normal response scale, and they 
translate to an absolute response change on the log-response scale which was used in 
practice (Paper III, Supplementary materials).  
 
In Paper III, results demonstrated that for hepatic vitamin A and liver weight data the 
BMD-based REP values were for some cases higher and for some cases lower than the 
NOEL-based REP values. The NOEL-based REP values were 1-5 times higher than the 
BMD-based REP values for female liver weight data after exposure to PCBs 128, 153 
and 156, female hepatic vitamin A data after exposure to PCBs 77, 153 and 156 and 
male hepatic vitamin A data after exposure to PCBs 77, 128 and 156. Whereas, for the 
remaining PCB congeners the BMD-based REP values were 1-3 times higher than the 
NOEL-based REP values. For the EROD activity data, the BMD-based REP values 
were in general 1-56 times higher than NOEL-based REP values (Table 1). 
   
The assumption of parallel dose-response curves was supported for most congeners 
considering the data on hepatic vitamin A and relative liver weight. This assumption 
was, however, not supported for most congeners considering the EROD activity data. 
Moreover, further statistical analysis showed that male and female BMD-based REP 
values were equal for most congeners in the case of hepatic vitamin A and liver weight 
endpoints, but only for PCB 128 in the case of hepatic EROD activity data (Figure 5, 
Table 1).  
 
Under the parallel curve assumption the BMD-based REP values become identical to 
the ED50-based REP values since the dose ratios do not depend on the selected response 
level, or BMR, in this case. In the case of non-parallel dose-response relationships the 
ED50-based REP values tended to be higher than BMD-based REP values (Table 1). 
Furthermore, in contrast to the BMD values that were derived in the low dose area, 
accurate estimation of ED50 values demands more reliable estimation of the maximum 
response level. Therefore in the cases where there is a lack of response information at 
high dose levels, ED50-based REP values can be less precise than BMD-based REP 
values. Among the endpoints investigated in Paper III this situation was most 
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prominent for PCB 156 (based on male liver weight data) where the very low ED50 
REP was due to estimation of ED50 for PCB 156 outside the range of observations.  
  
 
 
 
Figure 5. Michael-Menten equations fitted to hepatic vitamin A data (µg) observed in male and female 
Sprague-Dawley rats following subchronic exposure to PCB 156 (µg/kg bw/day) and PCB 126 (µg/kg 
bw/day). Squares and triangles indicate female and male data on PCB 126, respectively. Crosses and 
circles represent female and male data on PCB 156, respectively. According to the statistical analysis, the 
dose-response curves for PCB 126 and PCB 156 are parallel for the male data. The parallel curve 
assumption was also supported for the female data. The statistical analysis supports the assumption of 
equal REP values for the male and female data, i.e. 126malePCBk / 156malePCBk = 126femalePCBk /
156femalePCBk . Hence, the REP value (BMD ratio) is independent of the response level selected and can 
be summarized as a single value for male and female data.  
 
 
In Paper III, the uncertainty associated with the BMD-based REP values was 
presented as two-sided 90% confidence intervals. A confidence interval may also be 
implemented for ED50-based REP values, however such estimation is not possible for 
NO(A)EL-based REP values. The REP point estimates as well as the associated 
confidence intervals can be used as relative potency factors (RPFs) in cumulative risk 
assessments.   
 
REP values could be established based on one or more of the endpoints analysed for 
congeners assigned a TEF (PCBs 77, 105, 118 and 156) as well as congeners not 
assigned a TEF (PCBs 28, 128 and 153). The highest REP values were obtained for 
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relative liver weight; REP values based on decreased hepatic vitamin A levels were 
slightly lower; and the lowest REP values were in general obtained for data on hepatic 
EROD activity (Table 1). The BMD-based REP values corresponding to DL PCB 
congeners were similar to their corresponding established WHO-TEF values. For 
assessment of the cumulative effects of persistent chemical mixtures, the findings in 
Paper III suggest that in addition to the mode-of-action approach, development of a 
system that includes chemicals with similar effects despite their different underlying 
mechanisms of action could be useful.  
 
 
Table 1. Relative potency (REP) values estimated as BMD, ED50, and NO(A)EL ratios based on relative 
liver weight (%), hepatic vitamin A ( µg) and hepatic EROD activity (nmol/ mg protein/hr) observed in 
male and female rats after exposure to individual PCB congeners.  
 
 
PCB 
congener  TEF
a 
Liver weight Hepatic vitamin A Hepatic EROD activity 
BMD 
REP 
ED50 
REP  
NOEL 
REP  
BMD 
REP 
ED50 
REP 
NOEL 
REP  
BMD 
REP 
ED50 
REP 
LOELb 
REP 
MALE 
28        6.8e-07 8.6e-05 2.6e-06 
77 1.0e-03    9.0e-04 8.6e-03 1.1e-03 1.8e-04 3.7e-04 1.3e-05 
105 3.0e-04 5.0e-04 5.0e-04 2.0e-04 5.7e-04 5.7e-04 2.0e-04 7.9e-05 6.5e-05 2.3e-06 
118 3.0e-04       1.2e-05 5.9e-05 1.5e-05 
128     4.0e-05 4.0e-05 1.9e-04 4.9e-06 4.9e-06 2.4e-06 
153  5.4e-04 5.4e-04 2.3e-04 2.7e-04 2.7e-04 2.3e-04 2.1e-04 1.3e-03 2.9e-04 
156 3.0e-04 1.5e-03 5.0e-16 1.2e-03 4.5e-03 4.6e-03 1.2e-02 3.0e-04 2.3e-04 1.4e-05 
FEMALE 
28        2.4e-06 2.3e-06 2.5e-06 
77 1.0e-03    6.0e-04 6.0e-04 1.1e-03 2.9e-04 7.2e-04 1.1e-04 
105 3.0e-04 3.0e-03 3.0e-03 1.9e-03 3.2e-04 3.2e-04 2.3e-04 1.4e-04 1.1e-04 2.5e-06 
118 3.0e-04       1.1e-04 1.1e-04 5.9e-05 
128  4.1e-04 4.1e-04 2.0e-03 3.9e-05 3.9e-05 2.3e-05 5.4e-06 6.5e-06 2.3e-06 
153  7.0e-04 7.0e-04 2.0e-03 4.5e-05 4.5e-05 2.3e-05 7.5e-03 3.6e-02 2.4e-04 
156 3.0e-04 9.8e-03 9.8e-03 1.0e-02 3.7e-03 3.7e-03 1.1e-02c 6.2e-04 5.3e-04 1.2e-05 
 
aWHO TEF values (Van den Berg et al. 2006) have been adjusted to account for the use of PCB 126 as a 
reference compounds, i.e. by dividing with the TEF for PCB 126 (TEF = 0.1). 
bFor hepatic EROD activity data, a NOEL value could not be established for PCB 126 and the 
calculations have been based on LOEL values for all congeners. 
 
 
  
2.3.2 Establishment of the cumulative margin of exposure  
In Paper IV, a probabilistic approach for integrated evaluation of dose-response and 
exposure data was further developed and applied to estimate the cumulative MOE for 
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the combined exposure to DL PCBs 77, 105, 118, 156 and NDL PCB 153. There are a 
number of studies that have used a probabilistic risk assessment framework for MOE 
estimation, but these studies have mainly focused on pesticides (Bosgra et al. 2009; 
Muller et al. 2009). In contrast to the conventional MOE approaches, which are 
calculated as the ratio between a BMDL (or NO(A)EL) and a point estimate of the 
human exposure, the variability and uncertainty in both components of the MOE are 
taken into account under a probabilistic framework. Along these lines, a distribution 
(describing variability) for the MOE was estimated as the ratio between a distribution 
for a reference dose and a distribution for the human dietary exposure in Paper IV. 
The uncertainty in the respective distribution was also assessed in this process. Data 
on hepatic vitamin A from the same series of toxicity studies on individual PCB 
congeners that was used as basis in Paper III was used as an example endpoint for this 
analysis.  
 
In Paper IV, an RPF-based approach as well as an RPF-free approach was considered 
for estimating the cumulative MOE. In the RPF-based approach, the cumulative PCB 
exposure was estimated by the use of RPFs. Individual REPs derived for PCB 28, 
105, 118, 153 and 156 (using PCB 126 as reference) in Paper III were used in Paper 
IV as RPFs to express the concentration of individual compounds in equivalents of 
PCB 126 (Table 2). The analysis in Paper III suggested that these REPs were similar 
for male and female data except for PCB 153. In Paper IV, however, a 
common/single RPF was also used for male and female data on PCB 153 since they 
were close enough to be considered as similar in a practical context. The RPFs were 
assumed to be log-normally distributed, characterized by a geometric mean equal to 
the point estimates of the RPFs (Table 2) and a geometric standard deviation that was 
estimated from a two-sided 90% confidence interval established for each RPF (Table 
2). 
 
Under the RPF-based approach, the cumulative MOE was estimated by comparing 
the RfD for PCB 126 with the cumulative exposure expressed in terms of PCB 126 
equivalents. Under the RPF-free approach, the cumulative MOE is estimated by the 
use of compound specific MOEs. Detailed description of these two approaches can be 
found in the materials and methods section in Paper IV. 
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Table 2. Relative potency factors (RPFs) for individual PCB congeners (relative to PCB 126), based on 
hepatic Vitamin A data for male and female Sprague-Dawley rats. 
PCB 
Congener 
RPF 
(Lower bound (P5), Upper bound (P95)) 
PCB 28  NAa
PCB 77  9.0e-04 
(5.6e-04, 1.3e-03) 
PCB 105 4.5e-04 
(2.6e-04, 7.8e-04) 
PCB 118 NA 
PCB 153 1.5e-04 
(1.0e-04, 2.0e-04) 
PCB 156 4.5e-03 
(2.6e-03, 6.9e-03) 
 
a Not applicable:  There was no statistically significant difference between the saturated model and the 
no-response model, i.e. no dose-response relationship was observed. 
 
The 0.1st, 1st, 5th, and 50th percentiles of the cumulative MOE were estimated under 
the two approaches considered (Paper IV, Table 5). The lowest value for the 
cumulative MOE was 20; it suggests that 1 out of 1000 women have a MOE less than 
20 (and with high confidence this value is not less than 5, if also accounting for the 
uncertainty). The corresponding value for men was about 70. Depending on the 
percentile considered, the cumulative MOE could be a factor of 2 - 4 lower for women 
compared to men. This difference was mainly due to differences in the estimated RfD 
values for men and women, while the estimated exposure levels for men and women 
were similar (Paper IV, Tables 3 and 4). The results indicated that the cumulative 
MOE, more or less, reflected the MOE for PCB 126; the other PCB congeners had little 
contribution to the cumulative exposure, and thus the cumulative MOE (Figure 6).    
 
It has been discussed that the RPF-based and RPF-free approaches used in Paper IV 
are equivalent (van der Voet et al. 2009). However in practice, the implementation of 
the two approaches is different. The RPF-based approach requires the direct use of 
RPFs; such values are usually established as single (average/median) values for each 
compound and the uncertainty in the RPFs can also be taken into account, as 
discussed in Paper IV. However, in van der Voet (2009), the RPFs have been defined 
as the ratio between individual reference doses that accounts for both variability and 
uncertainty, i.e. not conventional BMD ratios based on experimental data only. Hence, 
the RPF-free approach can be considered as indirectly accounting for both variability 
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and uncertainty in relative potency. Thus, the main difference between the 
implementation of the two approaches discussed in Paper IV is that uncertainty in 
relative potency is only accounted for in the RPF-based approach, while both 
variability and uncertainty in relative potency is indirectly accounted for in the RPF-
free approach. This may explain the minor differences observed between the two 
approaches (Paper IV, Table 5).  
 
While the RPF-free approach accounts for variability (beside uncertainty) at the level 
of relative potency, it may be regarded to be more data intensive, compared to the 
RPF-based approach, since it requires detailed dose-response data for all compounds 
included. An advantage of the RPF-based approach is that the implementation of this 
approach only requires detailed dose-response information for the reference 
compound (PCB 126 in this case), and RPFs that have been derived in previous 
studies can be used. 
 
 
 
 
 
Figure 6. The relative contribution of individual PCB congeners (in terms of mean values) to the 
cumulative dietary PCB intake, in terms of PCB 126 equivalents, for men 17-74 years of age. A similar 
result was observed for women. 
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2.4 CONCLUSIONS  
This thesis work provides an important input to the evaluation and application of 
quantitative risk assessment methods thereby contributing to further development in 
this area.  
 
Establishment of dose-response relationship for different categories of effects, 
identification of strain and species differences, and assessment of chemical potency 
differences are elements that can be identified in hazard characterization, which is a 
central step in the risk assessment process. Part one of this thesis has demonstrated 
such evaluations, and it has discussed the advantages of performing detailed analysis of 
the entire dose-response data compared to using a NO(A)EL approach. More 
specifically, it was concluded that: 
 
 For most parameters investigated in Paper I, L-E and H/W data differed 
statistically in their response to TCDD treatment. In general L-E rats were 5-20 
times more sensitive than H/W rats, and this difference was in the range of 20 
to 40-fold in the case of hepatic foci. The strain differences were less 
uncertain (shorter confidence interval) for the retinoid parameters and EROD 
activity.  
 The BMD approach is more suitable than the NOAEL approach for evaluation 
of bone parameters considered in Paper II. BMDLs corresponding to a 
response level of 5% were in the same range as the NOAEL. It was concluded 
that the two strains are significantly different in their response to TCDD 
treatment, confirming the distinct role of AhR, with the L-E rat being the most 
sensitive strain. This difference was most pronounced (about 49-fold) for cross-
sectional area of proximal tibia.  
 For the PCB congeners considered in Paper III the BMD approach resulted in 
REP values that were in general more reliable compared to the NOEL and ED50 
approaches. In addition, our results support further development and use of 
endpoint specific ranking systems based on BMD-derived REP values for 
assessment of human exposure to mixtures of chemicals with similar as well 
as different mode of actions.  
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Part two of this thesis concerned development of quantitative approaches for risk 
characterization. The cumulative MOE was in this study estimated for a group of 
PCBs using reduction of hepatic retinoids as an example endpoint. A framework that 
accounts for variability and uncertainty, with regard to both components of the MOE, 
was applied. From Paper IV, it was concluded that: 
 
 The median of the 0.1st percentile for the cumulative MOE was about 20 for 
women, and about 70 for men. The cumulative MOE, more or less, reflected 
the MOE for PCB 126; the other PCB congeners had little contribution to the 
cumulative exposure, and thus the cumulative MOE.  
 The RPF-free approach more completely accounts for variability and 
uncertainty compared to the RPF-based approach. On the other hand, the 
RPF-based approach is less data intensive and can be more easily 
implemented in practice, allowing for a use of historical data on RPFs.  
 Compared to conventional MOE approaches, the approaches discussed in 
Paper IV provide an improved tool under which potential health concerns 
can be assessed by accounting for both variability and various uncertainties 
involved quantitatively, contributing to improving cumulative risk 
assessments.  
     
2.5 FUTURE PERSPECTIVES 
As has been discussed, the BMD approach is considered to be preferred over the 
NO(A)EL method for establishment of health-based guidance values or for assessment 
of differences in sensitivity between species, strains, genders, etc. One of the major 
advantages of the BMD approach is that it involves uncertainty analysis (e.g. 
accounting for sample size). So far, there are not many studies that have investigated 
the influence of study design on the BMD, i.e. the impact of dose placement, and 
number of animals distributed at each dose level, on the uncertainty in the BMD or 
BMD ratio. Further investigation of this issue may help to optimize animal use in 
toxicological studies, resulting in a better allocation of available resources. 
  
In the case of non-parallel dose-response relationships, REPs cannot be established as 
single values, i.e. the REP will depend on the BMR. How to account for the case of 
non-parallel dose-response curves when assessing the health impact of cumulative or 
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combined exposures is a future challenge. In general, further investigation of how to 
deal with non-dose-additive compounds by analyzing dose-response data of individual 
compounds as well as mixtures of compounds is of interest. 
 
In the probabilistic risk characterization framework discussed in Paper IV, the overall 
variability and uncertainty was estimated. An additional step is to include an approach 
that identifies the relative contribution of each source of variability/uncertainty with 
respect to the overall variability/uncertainty. This will help to identify the most 
important sources of MOE variation between individuals and/or the most important 
sources of uncertainty (that perhaps can be reduced e.g. by additional data collection).  
 
 
 
 
  
42 
 
3 ACKNOWLEDGEMENTS 
The work presented in this thesis was performed at the Institute of Environmental 
Medicine (IMM), Karolinska Institutet. I wish to use this opportunity to express my 
sincere thanks to those who I owe my progress to their help and without their assistance 
this work was not possible! 
 
I deem it my duty to thank Professor Helen Håkansson for taking me as a PhD student 
and providing me support and guidance during these years! Thank you for your 
encouragements and patience to improve my research abilities. Thanks for introducing 
me the field of health risk assessment and thanks for your positive attitude to the new 
methodologies in this filed and letting me apply them! 
 
I would like to express my gratitude to Dr. Salomon Sand, for all that he has taught me. 
Thank you for interesting scientific discussions even over the phone, for your constant 
guidance and for endless patience and support and positive and encouraging attitude. 
 
My mentor Dr. Reza Mohammadi, thanks for being around whenever I needed your 
help and advice and for your positive and relaxing views in solving the issues. 
 
Many thanks to Ali, for your loyal friendship, for always being helpful and supportive! 
For nice chats and all the funs and for your help in arranging my PhD dissertation! 
 
Emma and Anna, thank you for your great friendship, for sharing your experiences of 
life in general and feminine experiences in particular. Thank you for all your kindness! 
 
My thanks to the past and present members of the unit; Kina thank you for always 
being kind and helpful; Daniel for funs and laughs; Mattias for your advices and nice 
chats; Inga-Lill for all your helps and Swedish-English translations; thanks are 
extended to Annika, Krister, Maria, Sabina, Lubna, Robert, Fillip, Lina, Lauy, Vaninna, 
and Katarina for making IMM a nice place to work! 
 
Firoozeh and Shokufeh, thank you for your wonderful friendship, for the fruitful 
discussions and having lots of fun and for generous love and support! 
 
Dr. Zendedel and Marzieh for your kind friendship, for introducing Stockholm to us 
and sharing up and downs of the life! I would like to acknowledge you for introducing 
IMM to me as a nice place to pursue my study! 
 
My sincere thanks to my parents, for all of invaluable supports and encouragements 
during my life. My family Alireza, Yaser, Leili and Amir, thank you for your 
continuous caring and support. You are the best! 
 
Last but not the least, I would like to thank my beloved Isaac for all his 
encouragements and supports throughout the long journey of our common life! My 
thanks and loves to my girls Fatemeh and Setayesh who light up my life every day! 
Thank you for your patience when mommy was away for her study! 
 
43 
 
4 REFERENCES 
 
Ahlborg UG, Becking GC, Birnbaum LS, Brouwer A, Derks HJGM, Feeley M, Golor 
G, Hanberg A, Larsen JC, Liem AKD, Safe S, Schlatter C, Waern F, Younes M, Yrj. 
1994. Toxic equivalency factors for dioxin-like PCBs, Report on WHO-ECEH and 
IPCS consultation, December 1993. 
 
Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. 1994a. Dose-response assessment 
for developmental toxicity. II. Comparison of generic benchmark dose estimates with 
no observed adverse effect levels. Fundam Appl Toxicol 23(4): 487-495. 
 
Allen BC, Kavlock RJ, Kimmel CA, Faustman EM. 1994b. Dose-response assessment 
for developmental toxicity. III. Statistical models. Fundam Appl Toxicol 23(4): 496-
509. 
 
Allen BC, Strong PL, Price CJ, Hubbard SA, Daston GP. 1996. Benchmark dose 
analysis of developmental toxicity in rats exposed to boric acid. Fundam Appl Toxicol 
32(2): 194-204. 
 
Bailer AJ, Noble RB, Wheeler MW. 2005. Model uncertainty and risk estimation for 
experimental studies of quantal responses. Risk Anal 25(2): 291-299. 
 
Barton HA, Andersen ME, Allen BC. 1998. Dose-response characteristics of uterine 
responses in rats exposed to estrogen agonists. Regul Toxicol Pharmacol 28(2): 133-
149. 
 
Becker W, Pearson M. 2002. Riksmaten 1997-98. Kostvanor och näringsintag i 
Sverige. 
 
Berry CL. 1988. The no-effect level and optimal use of toxicity data. Regul Toxicol 
Pharmacol 8(4): 385-388. 
 
Bokkers BG, Slob W. 2005. A comparison of ratio distributions based on the NOAEL 
and the benchmark approach for subchronic-to-chronic extrapolation. Toxicol Sci 
85(2): 1033-1040. 
 
Bokkers BG, Slob W. 2007. Deriving a data-based interspecies assessment factor using 
the NOAEL and the benchmark dose approach. Crit Rev Toxicol 37(5): 355-373. 
 
Boobis AR, Ossendorp BC, Banasiak U, Hamey PY, Sebestyen I, Moretto A. 2008. 
Cumulative risk assessment of pesticide residues in food. Toxicol Lett 180(2): 137-150. 
 
Bosgra S, Bos PM, Vermeire TG, Luit RJ, Slob W. 2005. Probabilistic risk 
characterization: an example with di(2-ethylhexyl) phthalate. Regul Toxicol Pharmacol 
43(1): 104-113. 
 
Bosgra S, van der Voet H, Boon PE, Slob W. 2009. An integrated probabilistic 
framework for cumulative risk assessment of common mechanism chemicals in food: 
an example with organophosphorus pesticides. Regul Toxicol Pharmacol 54(2): 124-
133. 
 
Budtz-Jorgensen E, Grandjean P, Keiding N, White RF, Weihe P. 2000. Benchmark 
dose calculations of methylmercury-associated neurobehavioural deficits. Toxicol Lett 
112-113: 193-199. 
 
Budtz-Jorgensen E, Keiding N, Grandjean P. 2001. Benchmark dose calculation from 
epidemiological data. Biometrics 57(3): 698-706. 
44 
 
 
Budtz-Jorgensen E, Keiding N, Grandjean P. 2004. Effects of exposure imprecision on 
estimation of the benchmark dose. Risk Anal 24(6): 1689-1696. 
 
Chu I, Nakai J, Yagminas A, Poon R, Valli T, Håkansson H, Bergman Å. 2000. 
Toxicity of 2,3,3’,4,4’,5-hexachlorobiphenyl (PCB 156) in rats. Organohalogen 
compounds 49: 185-188. 
 
Chu I, Poon R, Yagminas A, Lecavalier P, Hakansson H, Valli VE, Kennedy SW, 
Bergman A, Seegal RF, Feeley M. 1998. Subchronic toxicity of PCB 105 (2,3,3',4,4'-
pentachlorobiphenyl) in rats. J Appl Toxicol 18(4): 285-292. 
 
Chu I, Villeneuve DC, Yagminas A, Lecavalier P, Hakansson H, Ahlborg UG, Valli 
VE, Kennedy SW, Bergman A, Seegal RF, et al. 1995. Toxicity of PCB 77 (3,3',4,4'-
tetrachlorobiphenyl) and PCB 118 (2,3',4,4'5-pentachlorobiphenyl) in the rat following 
subchronic dietary exposure. Fundam Appl Toxicol 26(2): 282-292. 
 
Chu I, Villeneuve DC, Yagminas A, LeCavalier P, Poon R, Feeley M, Kennedy SW, 
Seegal RF, Hakansson H, Ahlborg UG, et al. 1994. Subchronic toxicity of 3,3',4,4',5-
pentachlorobiphenyl in the rat. I. Clinical, biochemical, hematological, and 
histopathological changes. Fundam Appl Toxicol 22(3): 457-468. 
 
Chu I, Villeneuve DC, Yagminas A, Lecavalier P, Poon R, Feeley M, Kennedy SW, 
Seegal RF, Hakansson H, Ahlborg UG, Valli VE, Bergman A. 1996a. Toxicity of 
2,2',4,4',5,5'-hexachlorobiphenyl in rats: effects following 90-day oral exposure. J Appl 
Toxicol 16(2): 121-128. 
 
Chu I, Villeneuve DC, Yagminas A, Lecavalier P, Poon R, Hakansson H, Ahlborg UG, 
Valli VE, Kennedy SW, Bergman A, Seegal RF, Feeley M. 1996b. Toxicity of 2,4,4'-
trichlorobiphenyl in rats following 90-day dietary exposure. J Toxicol Environ Health 
49(3): 301-318. 
 
Clewell HJ, Crump KS. 2005. Quantitative estimates of risk for noncancer endpoints. 
Risk Anal 25(2): 285-289. 
 
Clewell HJ, Lawrence GA, Calne DB, Crump KS. 2003. Determination of an 
occupational exposure guideline for manganese using the benchmark method. Risk 
Anal 23(5): 1031-1046. 
 
Crump K. 2002. Critical issues in benchmark calculations from continuous data. Crit 
Rev Toxicol 32(3): 133-153. 
 
Crump KS. 1984. A new method for determining allowable daily intakes. Fundam 
Appl Toxicol 4(5): 854-871. 
 
Crump KS. 1995. Calculation of benchmark doses from continuous data. Risk Anal 15: 
79-89. 
 
Davis JA, Gift JS, Zhao QJ. 2011. Introduction to benchmark dose methods and U.S. 
EPA's benchmark dose software (BMDS) version 2.1.1. Toxicol Appl Pharmacol 
254(2): 181-191. 
 
Dorne JL, Walton K, Renwick AG. 2001. Uncertainty factors for chemical risk 
assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. 
Food Chem Toxicol 39(7): 681-696. 
 
Dorne JL, Walton K, Renwick AG. 2004. Human variability in the renal elimination of 
foreign compounds and renal excretion-related uncertainty factors for risk assessment. 
Food Chem Toxicol 42(2): 275-298. 
 
45 
 
Edler L, Poirier K, Dourson M, Kleiner J, Mileson B, Nordmann H, Renwick A, Slob 
W, Walton K, Wurtzen G. 2002. Mathematical modelling and quantitative methods. 
Food Chem Toxicol 40(2-3): 283-326. 
 
EFSA. 2005. Opinion of the Scientific Panel on Contaminants in the Food Chain on a 
request from the Commission related to the presence of non dioxin-like polychlorinated 
biphenyls (PCB) in feed and food. The EFSA Journal 284: 1-137. 
 
EFSA. 2009a. Guidance of the Scientific Committee on a request from EFSA on the 
use of the benchmark dose approach in risk assessments The EFSA Journal 1150: 1 - 
72. 
 
EFSA. 2009b. Cadmium in food. Scientific Opinion of the Panel on Contaminants in 
the Food Chain. The EFSA Journal 980: 1-139. 
 
Falk-Filipsson A, Hanberg A, Victorin K, Warholm M, Wallen M. 2007. Assessment 
factors--applications in health risk assessment of chemicals. Environ Res 104(1): 108-
127. 
 
Faustman EM, Allen BC, Kavlock RJ, Kimmel CA. 1994. Dose-response assessment 
for developmental toxicity. I. Characterization of database and determination of no 
observed adverse effect levels. Fundam Appl Toxicol 23(4): 478-486. 
 
Fowles JR, Alexeeff GV, Dodge D. 1999. The use of benchmark dose methodology 
with acute inhalation lethality data. Regul Toxicol Pharmacol 29(3): 262-278. 
 
Gaylor DW, Aylward LL. 2004. An evaluation of benchmark dose methodology for 
non-cancer continuous-data health effects in animals due to exposures to dioxin 
(TCDD). Regul Toxicol Pharmacol 40(1): 9-17. 
 
Gaylor DW, Slikker W, Jr. 1990. Risk assessment for neurotoxic effects. 
Neurotoxicology 11(2): 211-218. 
 
Jacobson JL, Janisse J, Banerjee M, Jester J, Jacobson SW, Ager JW. 2002. A 
benchmark dose analysis of prenatal exposure to polychlorinated biphenyls. Environ 
Health Perspect 110(4): 393-398. 
 
Kavlock RJ, Allen BC, Faustman EM, Kimmel CA. 1995. Dose-response assessments 
for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam 
Appl Toxicol 26(2): 211-222. 
 
Kim AH, Kohn MC, Portier CJ, Walker NJ. 2002. Impact of physiologically based 
pharmacokinetic modeling on benchmark dose calculations for TCDD-induced 
biochemical responses. Regul Toxicol Pharmacol 36(3): 287-296. 
 
Kodell RL, Howe RB, Chen JJ, Gaylor DW. 1991. Mathematical modeling of 
reproductive and developmental toxic effects for quantitative risk assessment. Risk 
Anal 11(4): 583-590. 
 
Kortenkamp A. 2007. Ten years of mixing cocktails: a review of combination effects of 
endocrine-disrupting chemicals. Environ Health Perspect 115 Suppl 1: 98-105. 
 
Krewski D, Van Ryzin J. 1981. Dose response models for quantal response toxicity 
data. In: Statistics and Related Topics,  (Csorgo D, Dawson D, Rao JNK, Saleh E, eds). 
North-Holland, Amesterdam, 201-231. 
 
Kroes R, Muller D, Lambe J, Lowik MR, van Klaveren J, Kleiner J, Massey R, Mayer 
S, Urieta I, Verger P, Visconti A. 2002. Assessment of intake from the diet. Food Chem 
Toxicol 40(2-3): 327-385. 
 
46 
 
Kuljus K, von Rosen D, Sand S, Victorin K. 2006. Comparing experimental designs for 
benchmark dose calculations for continuous endpoints. Risk Anal 26(4): 1031-1043. 
 
Kupper LL, Portier C, Hogan MD, Yamamoto E. 1986. The impact of litter effects on 
dose-response modeling in teratology. Biometrics 42(1): 85-98. 
 
Lecavalier P, Chu I, Yagminas A, Villeneuve DC, Poon R, Feeley M, Hakansson H, 
Ahlborg UG, Valli VE, Bergman A, Seegal RF, Kennedy SW. 1997. Subchronic 
toxicity of 2,2',3,3',4,4'-hexachlorobiphenyl in rats. J Toxicol Environ Health 51(3): 
265-277. 
 
Muller AK, Bosgra S, Boon PE, van der Voet H, Nielsen E, Ladefoged O. 2009. 
Probabilistic cumulative risk assessment of anti-androgenic pesticides in food. Food 
Chem Toxicol 47(12): 2951-2962. 
 
Murrell JA, Portier CJ, Morris RW. 1998. Characterizing dose-response: I: Critical 
assessment of the benchmark dose concept. Risk Anal 18(1): 13-26. 
 
Pieters MN, Kramer HJ, Slob W. 1998. Evaluation of the uncertainty factor for 
subchronic-to-chronic extrapolation: statistical analysis of toxicity data. Regul Toxicol 
Pharmacol 27(2): 108-111. 
 
Price PS, Keenan RE, Swartout JC, Gillis CA, Carlson-Lynch H, Dourson ML. 1997. 
An approach for modeling noncancer dose responses with an emphasis on uncertainty. 
Risk Anal 17(4): 427-437. 
 
Pufulete M, Battershill J, Boobis A, Fielder R. 2004. Approaches to carcinogenic risk 
assessment for polycyclic aromatic hydrocarbons: a UK perspective. Regul Toxicol 
Pharmacol 40(1): 54-66. 
 
Rai K, Van Ryzin J. 1985. A dose-response model for teratological experiments 
involving quantal responses. Biometrics 41(1): 1-9. 
 
Renwick AG. 1993. Data-derived safety factors for the evaluation of food additives and 
environmental contaminants. Food Addit Contam 10(3): 275-305. 
 
Renwick AG, Barlow SM, Hertz-Picciotto I, Boobis AR, Dybing E, Edler L, 
Eisenbrand G, Greig JB, Kleiner J, Lambe J, Muller DJ, Smith MR, Tritscher A, 
Tuijtelaars S, van den Brandt PA, Walker R, Kroes R. 2003. Risk characterisation of 
chemicals in food and diet. Food Chem Toxicol 41(9): 1211-1271. 
 
Renwick AG, Dorne JL, Walton K. 2000. An analysis of the need for an additional 
uncertainty factor for infants and children. Regul Toxicol Pharmacol 31(3): 286-296. 
 
Sand S, Filipsson AF, Victorin K. 2002. Evaluation of the benchmark dose method for 
dichotomous data: model dependence and model selection. Regul Toxicol Pharmacol 
36(2): 184-197. 
 
Sand S, Portier CJ, Krewski D. 2011. A Signal-to-Noise Crossover Dose as the Point of 
Departure for Health Risk Assessment. Environ Health Perspect 119(12): 1766-1774. 
 
Sand S, Victorin K, Filipsson AF. 2008. The current state of knowledge on the use of 
the benchmark dose concept in risk assessment. J Appl Toxicol 28(4): 405-421. 
 
Sand S, von Rosen D, Eriksson P, Fredriksson A, Viberg H, Victorin K, Filipsson AF. 
2004. Dose-response modeling and benchmark calculations from spontaneous behavior 
data on mice neonatally exposed to 2,2',4,4',5-pentabromodiphenyl ether. Toxicol Sci 
81(2): 491-501. 
 
47 
 
Sand S, von Rosen D, Victorin K, Filipsson AF. 2006. Identification of a critical dose 
level for risk assessment: developments in benchmark dose analysis of continuous 
endpoints. Toxicol Sci 90(1): 241-251. 
 
Slob W. 1999. Thresholds in toxicilogy and risk assessment International Journal Of 
Toxicology 18(4): 259-268. 
 
Slob W. 2002. Dose-response modeling of continuous endpoints. Toxicol Sci 66(2): 
298-312. 
 
Slob W. 2007. What is a practical threshold? Toxicol Pathol 35(6): 848-849. 
 
Slob W, Moerbeek M, Rauniomaa E, Piersma AH. 2005. A statistical evaluation of 
toxicity study designs for the estimation of the benchmark dose in continuous 
endpoints. Toxicol Sci 84(1): 167-185. 
 
Slob W, Pieters MN. 1998. A probabilistic approach for deriving acceptable human 
intake limits and human health risks from toxicological studies: general framework. 
Risk Anal 18(6): 787-798. 
 
Swartout JC, Price PS, Dourson ML, Carlson-Lynch HL, Keenan RE. 1998. A 
probabilistic framework for the reference dose (probabilistic RfD). Risk Anal 18(3): 
271-282. 
 
Toyoshiba H, Walker NJ, Bailer AJ, Portier CJ. 2004. Evaluation of toxic equivalency 
factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by 
dioxin-like compounds. Toxicol Appl Pharmacol 194(2): 156-168. 
 
USEPA. 1995. The use of the benchmark dose (BMD) approach in health risk 
assessment. ( EPA/630/R-94/007). Risk Assessment Forum, U.S. Environmental 
Protection Agency, Washington, DC. 
 
USEPA. 2000. Supplementary guidance for conducting health risk assessment of 
chemical mixtures EPA/630/R-00/002. 
 
Walton K, Dorne JL, Renwick AG. 2004. Species-specific uncertainty factors for 
compounds eliminated principally by renal excretion in humans. Food Chem Toxicol 
42(2): 261-274. 
 
Van den Berg M, Birnbaum LS, Denison M, De Vito M, Farland W, Feeley M, Fiedler 
H, Hakansson H, Hanberg A, Haws L, Rose M, Safe S, Schrenk D, Tohyama C, 
Tritscher A, Tuomisto J, Tysklind M, Walker N, Peterson RE. 2006. The 2005 World 
Health Organization reevaluation of human and Mammalian toxic equivalency factors 
for dioxins and dioxin-like compounds. Toxicol Sci 93(2): 223-241. 
 
van der Voet H, Slob W. 2007. Integration of probabilistic exposure assessment and 
probabilistic hazard characterization. Risk Anal 27(2): 351-371. 
 
van der Voet H, van der Heijden GW, Bos PM, Bosgra S, Boon PE, Muri SD, 
Bruschweiler BJ. 2009. A model for probabilistic health impact assessment of exposure 
to food chemicals. Food Chem Toxicol 47(12): 2926-2940. 
 
Vermeire T, Stevenson H, Peiters MN, Rennen M, Slob W, Hakkert BC. 1999. 
Assessment factors for human health risk assessment: a discussion paper. Crit Rev 
Toxicol 29(5): 439-490. 
 
Wheeler MW, Bailer AJ. 2007. Properties of model-averaged BMDLs: a study of 
model averaging in dichotomous response risk estimation. Risk Anal 27(3): 659-670. 
 
48 
 
Wheeler MW, Bailer AJ. 2009. Benchmark dose estimation incorporating multiple data 
sources. Risk Anal 29(2): 249-256. 
 
WHO. 1999. Principles of the assessment of risks to human health from exposure to 
chemicals. (Environmental Health Criteria 210, World Health Organization, Geneva). 
 
WHO/IPCS. 2004. Harmonization document no. 1. IPCS risk assessment terminology. 
World Health Organization, Geneva. 
 
Zhou T, Ross DG, DeVito MJ, Crofton KM. 2001. Effects of short-term in vivo 
exposure to polybrominated diphenyl ethers on thyroid hormones and hepatic enzyme 
activities in weanling rats. Toxicol Sci 61(1): 76-82. 
 
 
 
